Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

Ladhani, Shamez; Andrews, Nick; Waight, Pauline; Hallis, Bassam; Matheson, Mary; England, Anna; Findlow, Helen; Bai, Xilian; Borrow, Ray; Burbidge, Polly; Pearce, Emma; Miller, Elizabeth

doi:10.1016/j.vaccine.2014.12.018

Cited by 16 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,21 However, compared with previous term (PCV13) and preterm (PCV7) studies, antibody concentrations after primary and booster vaccination are lower overall, resulting in lower seroprotection after primary vaccination. 4,5,8,9,22 Similarly, compared with the recent PCV13 preterm study, 7 lower IgG GMCs and seroprotection rates were seen for all serotypes. These differences may be due to the different laboratory testing methods used for serotype-specific antibody concentrations, but potential biological explanations include interactions with concurrently administered vaccines, the younger gestation of the study cohort, or our broad inclusion criteria encompassing infants with complex medical problems (representative of the preterm population).…”

Section: Discussionmentioning

confidence: 69%

“…However, lower antibody concentrations were seen in our study cohort compared with a recent cohort of term infants in the United Kingdom who received a reduced dose schedule, which was analyzed in the same laboratory. 22 In addition, we did not include any assessment of functional activity of the antibodies detected. Opsonophagocytic antibody titers may have allowed us to assess the potential clinical impact of schedule differences in more detail and should be considered in future studies.…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Kent

Ladhani²,

Andrews

et al. 2016

Pediatrics

Self Cite

View full text Add to dashboard Cite

on behalf of the PUNS Study Group abstract BACKGROUND AND OBJECTIVE: Premature infants have a higher risk of invasive pneumococcal disease and are more likely to have lower vaccine responses compared with term infants. Increasingly, immunization schedules are including a reduced, 2-dose, pneumococcal conjugate vaccine priming schedule. Our goal was to assess the immunogenicity of 3 commonly used 13-valent pneumococcal conjugate vaccine (PCV13) priming schedules in premature infants and their response to a 12-month booster dose.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Figurementioning

confidence: 99%

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Kent

Ladhani²,

Andrews

et al. 2016

Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

“…A trial conducted in the UK evaluated the MenC response following a 2 dose infant priming schedule at 3 and 4 months of age by the MCC vaccine administered, 2 doses of NeisVac-C Ò or Menjugate Ò or NeisVac-C Ò followed by Menjugate Ò or vice versa, Menjugate Ò followed by NeisVac-C Ò . 20 The results of this trial showed that MenC responses differed significantly according to MCC schedule. Those vaccinated with Menjugate Ò followed by NeisVac-C Ò had the lowest SBA titres, while those receiving NeisVac-C Ò / Menjugate Ò had the highest; suggesting the order in which the infants received the MCC affected their responses (Fig.…”

Section: Evidence Supporting a Single Infant Priming Dosementioning

confidence: 79%

Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

Findlow¹,

Borrow

2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

In 1999, the UK introduced meningococcal serogroup C conjugate (MCC) vaccination at 2, 3, 4 months of age with a single dose for children 1-18 y In 2006, the schedule was refined to a 2 dose priming schedule with a booster in the second year of life. In 2013, the number of priming doses was reduced to a single priming dose, the booster maintained at 12 months of age and an adolescent booster dose introduced. The paper presents the evidence supporting the reduction in the number of priming doses. A UK study provided evidence for reducing the priming doses of MCC-TT together with the positive correlation of lower quantity of antigen and serum bactericidal antibody (SBA) levels postprimary but a higher magnitude of the booster response. Another UK study, demonstrated one dose of MCC-TT or MCC-CRM 197 at 3 months gave comparable responses to 2 doses (SBA titres 8) both post-primary vaccination and postbooster Hib/MCC-TT at 12 months. However, the magnitude of the SBA GMT was higher in the MCC-TT primed postbooster. A single priming dose of MCC-TT (at 4 or 6 months) compared to 2 doses (2 and 4 months) gave higher SBA titres in all groups, post-primary and post-booster at 12-13 months, with the highest SBA responses observed in the 4 month single dose group. A study in Malta, comparing one dose of at (3 months) versus 2 doses of MCC-CRM 197 (3 and 4 months), showed a high proportion (>84.72%) of subjects achieving SBA titres 8 following a single dose. These studies show that a single-dose priming MCC vaccination in infancy is sufficient.

show abstract

“…Analysis of MenC serum bacterial antibody (SBA) responses in UK infants showed that MCC vaccines with different carrier proteins are not interchangeable. 13 Those infants vaccinated with MCC-CRM followed by MCC-TT had significantly reduced MenC and Hib responses compared to those vaccinated with 2 doses of MCC-CRM or MCC-TT, or MCC-TT followed by MCC-CRM (Fig. 5).…”

Section: Bystander Interferencementioning

confidence: 91%

“…5). 13 While none of the previously reported phenomena explain the reason for these reduced responses, immune interaction between the carrier proteins is the most likely explanation.…”

Section: Bystander Interferencementioning

confidence: 93%